Krishna Institute of Medical Sciences cash flow

Latest FY26

Cash from operations: ₹511cr−12.2% on FY25
Capital spending: ₹1,428cr+41.5% on FY25
Free cash flow: −₹917cr−₹427 cr in FY25
Cash from financing: ₹940cr+73.1% on FY25

₹ crore except per share

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

Changes in working capital
Adjustments to reconcile profit — non-cash items						FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	—	283	90.3	147	129
	—	0.0	0.0	−1.5	0.0
	—	203	177	47.0	30.5
	—	−17.7	−16.2	−2.3	−9.5
	—	3.8	0.0	−1.8	−3.0
	—	9.5	12.4	−2.1	−34.2
	—	−0.5	−21.7	0.0	−1.2
	—	−32.9	−13.3	−6.6	6.5
	—	−169	−93.4	−40.3	−62.8
	—	−12.2	154	15.8	12.0
	—	−19.0	−153	20.7	−11.4
	—	−19.1	0.0	−24.3	0.3
	—	3.8	−9.6	0.1	24.8
	—	0.0	0.0	0.0	4.8
	—	54.7	47.6	24.1	−34.5
	—	21.1	0.0	5.0	13.6
	—	−21.0	−22.6	−1.2	0.0
	—	24.2	7.4	13.2	−25.9
	—	0.0	−2.7	0.0	−0.2
	—	6.2	7.8	4.5	3.2
	—	12.4	0.7	4.2	2.7
Cash from operating activities
	273	331	558	460	485
	—	331	165	201	45.1
	—	662	723	661	530
	—	0.0	0.0	0.0	−2.5
	—	151	141	140	95.4
	—	511	582	521	432
Cash from investing activities
	—	1,428	1,009	647	526
	—	0.0	0.0	0.0	48.8
	—	0.0	47.2	1.4	2.6
	—	15.0	0.0	0.0	0.0
	—	0.0	178	74.7	216
	—	0.0	0.0	0.0	0.2
	—	8.4	0.0	0.0	0.0
	—	30.9	27.2	26.0	0.0
	—	0.0	350	0.0	0.0
	—	0.0	416	0.0	0.0
	—	11.3	8.6	1.6	10.7
	—	−10.8	−23.2	−7.5	162
	—	−1,452	−1,116	−753	−616
Cash from financing activities
	—	48.8	0.0	0.0	0.0
	—	156	87.8	181	0.0
	—	1,539	878	531	389
	—	210	83.7	17.7	241
	—	74.4	40.0	55.9	41.2
	—	0.0	123	59.3	18.7
	—	207	0.0	0.0	0.0
	—	940	543	217	88.3
	—	−0.6	8.7	−14.7	−95.2
	—	−0.6	8.7	−14.7	−95.2
	—	—	56.0	46.9	61.6
Reference items
	833	802	783	640	604
	19.8%	20.5%	25.8%	25.6%	27.5%
	−917	−917	−427	−126	−142
	—	—	651	492	—
	−₹22.93	−₹22.93	−₹10.68	−₹3.16	−₹3.56
	—	2.11×	1.40×	1.55×	1.18×
	—	151	141	140	95.4
	—	—	123	59.3	18.7

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

KIMS₹704.60

Krishna Institute of Medical Sciences Ltd.

· Pharma & Health

₹ CrorePeersAPOLLOHOSP MAXHEALTH FORTIS JUBLPHARMA INDGN ONESOURCE PFIZER POLYMEDMcap ₹28,184 Cr

View

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Adjustments to Reconcile Profit — Non-cash Items
+ Depreciation & Amortisation	129.3	146.5	90.3	283.2	—
+ Impairment Loss / (Reversal)	0.0	-1.5	0.0	0.0	—
+ Finance Costs	30.5	47.0	177.2	202.5	—
+ Interest Income	-9.5	-2.3	-16.2	-17.7	—
+ Fair Value (Gains) / Losses	-3.0	-1.8	0.0	3.8	—
+ Other Non-cash Items	-34.2	-2.1	12.4	9.5	—
+ Other Reconciling Items	-1.2	0.0	-21.7	-0.5	—
Changes in Working Capital
+ Inventories	6.5	-6.6	-13.3	-32.9	—
+ Trade Receivables — Current	-62.8	-40.3	-93.4	-168.5	—
+ Other Financial Assets — Current	12.0	15.8	153.7	-12.2	—
+ Other Financial Assets — Non-current	-11.4	20.7	-152.5	-19.0	—
+ Other Current Assets	0.3	-24.3	0.0	-19.1	—
+ Other Non-current Assets	24.8	0.1	-9.6	3.8	—
+ Other Bank Balances	4.8	0.0	0.0	0.0	—
+ Trade Payables — Current	-34.5	24.1	47.6	54.7	—
+ Other Financial Liabilities — Current	13.6	5.0	0.0	21.1	—
+ Other Financial Liabilities — Non-current	0.0	-1.2	-22.6	-21.0	—
+ Other Current Liabilities	-25.9	13.2	7.4	24.2	—
+ Other Non-current Liabilities	-0.2	0.0	-2.7	0.0	—
+ Provisions — Current	3.2	4.5	7.8	6.2	—
+ Provisions — Non-current	2.7	4.2	0.7	12.4	—
Cash from Operating Activities
Profit Before Tax (per I/S)	484.9	459.9	558.1	331.3	273.2
+ Total Adjustments (incl. Working Capital)	45.1	201.3	165.1	330.5	—
Cash from Operations (pre-tax)	530.0	661.2	723.2	661.8	—
+ Interest Received — Operating	-2.5	0.0	0.0	0.0	—
+ Income Taxes Paid	95.4	140.2	141.4	151.0	—
Cash from Operating Activities	432.1	521.1	581.8	510.8	—
Cash from Investing Activities
+ Acq of Fixed Assets (Capex)	525.7	647.3	1,008.9	1,427.9	—
+ Acq of Intangible Assets	48.8	0.0	0.0	0.0	—
+ Disp of Fixed Assets	2.6	1.4	47.2	0.0	—
+ Disp of Investment Property	0.0	0.0	0.0	15.0	—
+ Acq of Subsidiaries / Businesses (net)	216.4	74.7	178.4	0.0	—
+ Disp of Subsidiaries / Businesses (net)	0.2	0.0	0.0	0.0	—
+ Investment in Partnership Firms / LLPs	0.0	0.0	0.0	8.4	—
+ Loans & Advances Made	0.0	26.0	27.2	30.9	—
+ Payments on Futures / Forwards / Options / Swaps	0.0	0.0	350.0	0.0	—
+ Receipts on Futures / Forwards / Options / Swaps	0.0	0.0	415.7	0.0	—
+ Interest Received — Investing	10.7	1.6	8.6	11.3	—
+ Other Inflows / (Outflows) — Investing	161.8	-7.5	-23.2	-10.8	—
Cash from Investing Activities	-615.6	-752.6	-1,116.2	-1,451.7	—
Cash from Financing Activities
+ Proceeds from Issue of Shares	0.0	0.0	0.0	48.8	—
+ Payments — Change in Ownership of Subsidiaries	0.0	181.1	87.8	155.9	—
+ Proceeds from Borrowings	389.4	530.7	877.5	1,538.5	—
+ Repayment of Borrowings	241.1	17.7	83.7	209.5	—
+ Payment of Lease Liabilities	41.2	55.9	40.0	74.4	—
+ Interest Paid	18.7	59.3	122.9	0.0	—
+ Dividends Paid	0.0	0.0	0.0	207.2	—
Cash from Financing Activities	88.3	216.8	543.1	940.3	—
Net Changes in Cash (pre-FX)	-95.2	-14.7	8.7	-0.6	—
Net Changes in Cash	-95.2	-14.7	8.7	-0.6	—
Closing Cash	61.6	46.9	56.0	—	—
Reference Items
EBITDA	604.0	640.4	782.9	802.0	832.8
EBITDA Margin %	27.48	25.64	25.79	20.54	19.77
Free Cash Flow (CFO − Capex)	-142.4	-126.3	-427.1	-917.1	-917.1
Free Cash Flow to Equity	—	491.6	651.4	—	—
Free Cash Flow per Basic Share	-3.56	-3.16	-10.68	-22.93	-22.93
Cash Flow to Net Income	1.18	1.55	1.40	2.11	—
Cash Paid for Taxes	95.4	140.2	141.4	151.0	—
Cash Paid for Interest	18.7	59.3	122.9	—	—

As filed, sign as filed: a payment tagged as a positive magnitude in the filing stays positive here, so read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown — depth follows the filer, so a thin statement means a thin filing. Total Adjustments is the filer's own grand total of the reconciliation and spans BOTH the non-cash items and the working-capital block; Profit Before Tax plus it equals Cash from Operations (pre-tax). It can be reported when its components are not, so it is never a sum of the rows above it. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.